recurrent cervical carcinoma

Showing 1 - 25 of 32

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Recurrent Cervical Carcinoma Trial in United States (Laboratory

Active, not recruiting
  • Cervical Adenocarcinoma
  • +5 more
  • Laboratory Biomarker Analysis
  • Nivolumab
  • Birmingham, Alabama
  • +336 more
Jan 28, 2023

Human Papilloma Virus Circulating Tumor DNA in Cervical Cancer

Recruiting
  • Cervical Adenosquamous Carcinoma
  • +26 more
  • Biospecimen Collection
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 4, 2023

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

MRI and PET Imaging in Predicting Treatment Response in Stage

Active, not recruiting
  • Cervical Adenocarcinoma
  • +12 more
  • Computed Tomography
  • +5 more
  • Miami, Florida
  • +5 more
Oct 4, 2022

Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +49 more
  • Birmingham, Alabama
  • +1429 more
Aug 17, 2022

Malignant Female Reproductive System Tumor, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma Trial in Houston

Recruiting
  • Malignant Female Reproductive System Neoplasm
  • +24 more
  • Quality-of-Life Assessment
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 6, 2022

PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • +9 more
  • Radiotherapy for targeted lesions and PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma, Persistent Cervical Carcinoma Trial in Beijing (Tislelizumab plus

Recruiting
  • Recurrent Cervical Carcinoma
  • +9 more
  • Tislelizumab plus radiotherapy
  • Beijing, Beijing, China
    Lei Li
Apr 1, 2022

Targeted Therapy, Chemo, Recurrent Cervical Carcinoma Trial in Beijing (Donafenib combined with paclitaxel and platinum ± PD-1

Recruiting
  • Targeted Therapy
  • +6 more
  • Donafenib combined with paclitaxel and platinum ± PD-1 antibody
  • Beijing, Beijing, China
    Lei Li
Mar 26, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,

Recruiting
  • Recurrent Cervical Carcinoma
  • +5 more
  • Anti-PD-1 antibody camrelizumab
  • Albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (A combination of anti-PD-1

Completed
  • Recurrent Cervical Carcinoma
  • +4 more
  • A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Chemotherapy plus apatinib)

Completed
  • Recurrent Cervical Carcinoma
  • +5 more
  • Chemotherapy plus apatinib
  • Beijing, Beijing, China
    Lei Li
Mar 12, 2022

Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Tumor Trial in Houston (DNA

Active, not recruiting
  • Human Papillomavirus-16 Positive
  • +20 more
  • DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457
  • Durvalumab
  • Houston, Texas
    M D Anderson Cancer Center
Feb 11, 2022

Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)

Active, not recruiting
  • Recurrent Cervical Carcinoma
  • Metastatic Cervical Cancer
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2021

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in

Completed
  • Cervical Adenocarcinoma
  • +6 more
  • Los Angeles, California
  • +21 more
Apr 20, 2021

Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor Trial in Beijing (Combination of nimotuzumab and

Recruiting
  • Recurrent Cervical Carcinoma
  • +6 more
  • Combination of nimotuzumab and radiotherapy
  • Beijing, Beijing, China
    Lei Li
Dec 18, 2020

Chemo, Anti-pd-1 Antibody, Cervical Neuroendocrine Carcinoma Trial in Beijing (Drug therapy)

Recruiting
  • Chemotherapy
  • +6 more
  • Drug therapy
  • Beijing, Beijing, China
    Lei Li
Nov 15, 2020

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in

Completed
  • Cervical Adenocarcinoma
  • +3 more
  • Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001
  • Laboratory Biomarker Analysis
  • Birmingham, Alabama
  • +23 more
Aug 21, 2020

Cervical Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma Trial in Bronx (Palliative Therapy, Palliative Therapy +

Completed
  • Cervical Carcinoma
  • +9 more
  • Palliative Therapy
  • Palliative Therapy + idiographic
  • Bronx, New York
    Albert Einstein College of Medicine
Sep 13, 2019

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma Trial in United States (biological,

Completed
  • Cervical Adenocarcinoma
  • +7 more
  • Filgrastim
  • +4 more
  • Orange, California
  • +77 more
Aug 6, 2019

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in

Completed
  • Cervical Adenocarcinoma
  • +4 more
  • Los Angeles, California
  • +24 more
Jul 17, 2019

Advanced Malignant Tumor, Cervical Squamous Cell Carcinoma, Endometrial Carcinoma Trial in Scottsdale, Rochester (Laboratory

Completed
  • Advanced Malignant Neoplasm
  • +31 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Scottsdale, Arizona
  • +1 more
Jun 5, 2019

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified Trial in

Completed
  • Cervical Adenocarcinoma
  • +4 more
  • Brivanib Alaninate
  • Laboratory Biomarker Analysis
  • Phoenix, Arizona
  • +42 more
Mar 8, 2019

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma Trial in United States (Paclitaxel

Completed
  • Cervical Adenocarcinoma
  • +4 more
  • Paclitaxel Albumin-Stabilized Nanoparticle Formulation
  • Laboratory Biomarker Analysis
  • Aurora, Colorado
  • +25 more
Dec 17, 2018

Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma Trial in Philadelphia (Cisplatin,

Completed
  • Cervical Adenocarcinoma
  • +4 more
  • Philadelphia, Pennsylvania
    Gynecologic Oncology Group
Sep 18, 2018